2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Phat Le, MD, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer.
Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer (CRC).
In some cases, patients with oligometastatic CRC may be candidates for aggressive treatments like surgery and radiation, says Le. However, 60% to 70% of patients who receive these treatments will eventually recur.
As such, not every patient should be treated with surgery or radiation, says Le. Further research is needed to understand which patients are likely to benefit from aggressive therapies and which patients should be spared the potential complications that associated with them, concludes Le.
Related Content: